Triple therapy shows promise for intermediate liver cancer

This study tested a combination of three treatments for people with intermediate-stage liver cancer: a procedure that blocks blood flow to the tumor (TACE), drugs that help the immune system fight cancer (PD-1/PD-L1 inhibitors), and drugs that stop blood vessel growth (VEGF-TKI or bevacizumab). The goal was to see if this triple therapy is safe and effective. The study included 941 participants who had not received prior treatment for their liver cancer. Researchers measured how long patients lived without their cancer getting worse and overall survival.